ASK PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 223 million yuan, a year-on-year increase of 75.81%Zhitong·Oct 28, 2025 at 05:39 AM300361002755+2.35%
Aosaikang: Innovative drug ASKB589 will announce clinical research data at the 2025 ESMO Annual MeetingZhitong·Oct 20, 2025 at 02:51 AM300361002755+2.35%
Aosaikang's subsidiary signs ASKG712 project licensing agreementZhitong·Oct 16, 2025 at 07:15 PM002755+2.35%300361
The innovative drug sector adjusted at the beginning of the trading session, with Aosaikang hitting the limit down, followed by declines in Cosunter, Jimin Health, Huili Pharmaceutical-W, Saili Medical, Rongchang Bio, Wanbangde, and othersZhitong·Sep 25, 2025 at 08:40 PM300436+3.42%300361
Aosaikang: Net profit of 160 million yuan in the first half of 2025, a year-on-year increase of 111.64%Zhitong·Aug 28, 2025 at 06:29 AM300361002755+2.35%
Aosaikang: Expected net profit in the first half of the year to increase by 78.58%-131.50% year-on-yearZhitong·Jul 14, 2025 at 03:54 AM002755+2.35%300361
Aosaikang: The results of the Phase III clinical study of Liraglutide Tablets were published in The Lancet Respiratory MedicineZhitong·Jun 23, 2025 at 04:03 AM300361002755+2.35%
Aosaikang's subsidiary Methotrexate Injection has obtained a drug registration certificateZhitong·Jun 22, 2025 at 03:33 AM002755+2.35%300361
Aosaikang's major shareholder Su Yang Investment reduced its stake by 1.50%Zhitong·May 7, 2025 at 06:52 AM300361002755+2.35%
Aosaikang released its first-quarter performance, with a net profit attributable to the parent company of 54.7303 million yuan, a year-on-year increase of 73.50%Zhitong·Apr 27, 2025 at 04:12 AM300361002755+2.35%
Beijing Aosaikang Pharmaceutical Co., Ltd.'s (SZSE:002755) Shares Climb 25% But Its Business Is Yet to Catch UpSimplywall·Mar 15, 2025 at 09:16 PM300361
Aosaikang: The registration application for the listing of Isavuconazole Sulfate Capsules has been acceptedZhitong·Feb 10, 2025 at 03:28 AM002755+2.35%300361
The anti-tumor Class 1 new drug Liratinib tablets have been approved for market launch生物谷·Jan 31, 2025 at 07:40 PM300361
